Ongoing phase 3 trials
| Trial name . | Study arms . | Population . | Primary end point . |
|---|---|---|---|
| IMpactMF (NCT045761) | 9.4 mg/kg IV every 3 weeks vs BAT∗ | DIPSS intermediate-2 + MF, refractory to JAKi | OS |
| IMerge (NCT02598661) | 7.5 mg/kg IV every 4 weeks vs placebo | IPSS low- to intermediate-risk MDS, transfusion dependence refractory to ESA | TI |
| Trial name . | Study arms . | Population . | Primary end point . |
|---|---|---|---|
| IMpactMF (NCT045761) | 9.4 mg/kg IV every 3 weeks vs BAT∗ | DIPSS intermediate-2 + MF, refractory to JAKi | OS |
| IMerge (NCT02598661) | 7.5 mg/kg IV every 4 weeks vs placebo | IPSS low- to intermediate-risk MDS, transfusion dependence refractory to ESA | TI |
Hydroxyurea, thalidomide or analog, IFN, danazol, HMA, or chemotherapy; excludes JAKi.